GEN inCode has developed a range of patented molecular testing products that utilise AI, bioinformatics and a globally recognised clinical evidence base to provide predictive analysis of a patient's health risk. Proprietary algorithms are used to predict the probability of adverse events, resulting in a comprehensive evaluation that provides key insights into a patient's susceptibility to disease and clinically actionable results that empower patients to take steps to reduce their risk.
Healthcare is shifting away from ‘one-size-fits-all’ treatments towards targeted approaches that utilise patients’ genetic information to inform healthcare decisions. GEN inCode's advanced predictive modelling of patient data is helping personalise treatment pathways by more accurately addressing disease risk and enabling healthcare practitioners to identify high-risk patients and proactively develop targeted treatment and prevention plans. These innovative solutions are helping to transform the delivery of healthcare, reduce costs and improve patient outcomes.
We are delighted to complete the institutional round of funding and welcome our new institutional investors. The funding will prepare the Company for accelerated growth and international scale and supports our regulatory and clinical pathway into the US market.
Matthew Walls, Chairman and CEO of GEN inCode
